ClinicalTrials.gg
RecruitingNCT04858867RESETUpdated Oct 10, 2023

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

An interventional study of rhTSH-stimulated I-124 dosimetry and Intra-therapeutic I-131 dosimetry in Differentiated Thyroid Cancer, sponsored by Leiden University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Leiden University Medical Center · Not applicable, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Thyroid Neoplasms with a site in Netherlands — 6 open to participants now, 8 under way, 1 of them phase 3. Thyroid Neoplasms · Netherlands.

Planned enrollment
21st of 24
12 · median 76
Started
2022
with 2 others
No phase
6 of 28
2 open now
Registered
21st of 28
by date
Lead sponsor
3 of 28
Leiden University Medical Center

Among the 28 studies in Thyroid Neoplasms with a site in Netherlands, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 with no phase, and was the 21st registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 28 studies in Thyroid Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Thyroid Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

This is a single-centre open label phase II study evaluating the effect of lenvatinib treatment for restoring radioiodine uptake and retention in radioiodine-refractory (RAI-R) thyroid cancer to warrant I-131 therapy.

Read the detailed description

RAI-R DTC patients starting standard-of-care lenvatinib treatment will be included in this study. Prior to lenvatinib treatment, patients will undergo I-124 PET/CT to quantify RAI uptake and retention at baseline. The first half of the intended sample size (cohort 1) will be treated with lenvatinib for a total of 12 weeks. After 6- and 12-week treatment, patients will undergo I-124 PET/CT dosimetry to evaluate the redifferentiation effect, assess expected absorbed lesion doses and maximum tolerable activity. Results between 6- and 12-week lenvatinib treatment will be compared to select the lenvatinib treatment duration that leads to highest extent of redifferentiation. The next patients (cohort 2) will then receive lenvatinib for either 6 or 12 weeks.

Patients will undergo subsequent I-131 therapy if a clinically meaningful lesion dose is expected and toxicity is deemed acceptable. For all patients eligible for I-131 therapy, lenvatinib is discontinued prior to administration of I-131 and intra-therapeutic I-131 SPECT dosimetry will be performed for dose verification. Patients who are not eligible for I-131 therapy, will continue lenvatinib treatment at the discretion of the treating physician.

Biopsies are performed at baseline and after 6-week lenvatinib treatment to evaluate alterations at the transcriptional and translational level in biopted tumor lesions. Patients will be followed up according to current guidelines for a total of 9 months after initiating lenvatinib treatment. Metabolic and biochemical response will be assessed using F-18 FDG PET/CT and Tg levels, respectively.

03

Conditions studied

  • Differentiated Thyroid Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of
  • or cytologically confirmed DTC (including papillary, follicular or Hürthle Cell carcinoma)
  • Progressive (biochemical or anatomic) disease for which lenvatinib is started as standard treatment at the discretion of the treating physician
  • at baseline imaging (F-18 FDG PET) according to the definition of the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 with at least one lesion ≥1.0 cm in the longest diameter for a non-lymph node or ≥1.5 cm in the short axis for a lymph node.
  • RAI-R disease on structural imaging, defined as any one of the following:

    • lesions that are not RAI-avid on a diagnostic or intra-therapeutic RAI scanperformed prior to enrolment in the current study
    • RAI-avid metastatic lesions which remained stable in size or progressed according to 1.1 criteria despite RAI treatment. Absence of response is observed during 6-9 months after high dose I-131 therapy.
  • No recent treatment for thyroid cancer:

    • No prior I-131 therapy is allowed \<6 months prior to initiation of therapy on this protocol (a diagnostic study using \<400 MBq of I-131 is not considered 131I therapy)
    • No external beam radiation therapy is allowed \<4 weeks prior to initiation of therapy on this protocol. (Previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)
  • (ECOG) performance status ≤2 (or ≥60%)
  • ≥3 months
  • Ability to swallow and retain orally-administered medication and no gastrointestinal abnormalities that may alter absorption
  • Creatinine ≤1.5 mg/dL (≤133 µmol/L) or estimated (eGFR) (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) ≥50 mL/min/1.73m2 or 24-hour urine ≥50 mL/min/1.73m2
  • Adequate blood coagulation function as evidenced by an (INR) ≤1.5
  • Adequate bone marrow function with:

    • ≥1.5*10\^9 /L
    • ≥9 g/dL (5.6 mmol/L)
    • ≥100*10\^9 /L
  • Adequate liver function with

    • Albumin ≥25 g/L
    • Total \<1.5x institutional (ULN) with an exception for patients with Gilbert's syndrome
    • and alanine aminotransferase ≤3x institutional ULN (≤5x ULN if subject has liver metastases)
  • Negative pregnancy test within 7 days prior to starting the study for premenopausal women. Women can be included without pregnancy test if they are either surgically sterile or have been for ≥1 year.
  • Sexually active women of must agree to use a highly effective method of during the study and for at least 6 months after the last study treatment administration.Sexually active males patients must agree to use condom during the study and for at least 6 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception. Effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intrauterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • Concomitant or previous within the last 3 years. Patients are eligible for this study if they have been disease-free of the previous malignancy for at least 3 years, have a history of completely resected non-melanoma skin cancer and/or have indolent secondary malignancies.
  • Symptomatic or untreated or or spinal cord compression
  • Evidence of cardiovascular risk including any of the following:

    • arrhythmias
    • Acute coronary syndromes, severe/unstable angina
    • Symptomatic congestive heart failure
  • Use of other drugs within 28 days preceding the first dose of treatment in this study or during the study
  • Have a known immediate or delayed reaction or idiosyncrasy to drugs chemically related to lenvatinib and/or to Thyrotropin alfa (human recombinant thyrotropin) or other known contents of the two drugs.
  • Inability to follow a low iodine diet or requiring medication with high content in iodide (e.g. amiodarone)
  • Patients who received iodinated intravenous contrast as part of a radiographic procedure within 6-8 weeks of study registration. Patients are eligible for this study if urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant, lactating or breast feeding women
  • Any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study
  • Unwillingness or inability to comply with study and follow-up procedures
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    Cohort 1

    Study procedures * Lenvatinib during week 1-12 * rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12 * rhTSH-stimulated I-131 therapy at week 13 (if eligible) * Intra-therapeutic I-131 dosimetry at week 13 (if eligible) * Biopsy at week 0 and 6 * F-18 FDG PET/CT at week 0, 6, 12, 24 and 36 * Tg levels at week 0, 6, 12, 24 and 36 * QoL assessment at week 0, 6, 12, 24 and 36

    Radiation: rhTSH-stimulated I-124 dosimetry · Radiation: Intra-therapeutic I-131 dosimetry

  • Other
    Cohort 2

    Study procedures (in case of 12-wk lenvatinib): * Lenvatinib during week 1-12 * rhTSH-stimulated I-124 dosimetry at week 0 and 12 * rhTSH-stimulated I-131 therapy at week 13 (if eligible) * Intra-therapeutic I-131 dosimetry at week 13 (if eligible) * Biopsy at week 0 and 6 * F-18 FDG PET/CT at week 0, 12, 24 and 36 * Tg levels at week 0, 6, 12, 24 and 36 * QoL assessment at week 0, 6, 12, 24 and 36 Study procedures (in case of 6-wk lenvatinib) * Lenvatinib during week 1-6 * rhTSH-stimulated I-124 dosimetry at week 0 and 6 * rhTSH-stimulated I-131 therapy at week 13 (if eligible) * Intra-therapeutic I-131 dosimetry at week 13 (if eligible) * Biopsy at week 0 and 6 * F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36 * Tg levels at week 0, 6, 12, 24, 30 and 36 * QoL assessment at week 0, 6, 12, 24, 30 and 36

    Radiation: rhTSH-stimulated I-124 dosimetry · Radiation: Intra-therapeutic I-131 dosimetry

Interventions

  • RadiationrhTSH-stimulated I-124 dosimetry

    Preparation: * Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion * Thyrogen injections 24 and 48h prior to I-124 ingestion Procedures following Jentzen et al: * Ingestion of capsule with 37±10% MBq I-124 * I-124 PET/CT at 24 and 96h post-ingestion * Blood draws at 2, 24 and 96h post-ingestion * Whole body counting at 2, 24 and 96h post-ingestion

  • RadiationIntra-therapeutic I-131 dosimetry

    Procedures following EANM guidelines: * I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion * Blood draws at 2, 6, 24, 96 and 144h post-ingestion * Whole body counting at 2, 6, 24, 96 and 144h post-ingestion

This study also gives LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Fraction of RAI-R thyroid cancer patients who are eligible for I-131 therapy after 6- or 12-week lenvatinib treatment

    Patients are deemed eligible for I-131 therapy if the therapeutic activity (max. 7.4 GBq) will lead to (1) an expected absorbed dose \>20 Gy in at least one lesion, (2) a blood dose \<2 Gy and (3) whole body retention \<3.0 or 4.4 GBq at 48h post-ingestion in presence or absence of diffuse pulmonary metastases, respectively.

    Time frame: 2-3 months after completed inclusion of all study participants

Secondary outcomes

  1. Extent of RAI uptake at baseline and after 6- or 12-week lenvatinib

    Assessing expected absorbed dose \[Gy\] per lesion or critical organ using I-124 PET/CT, whole body counting and blood sampling

    Time frame: 0, 6, 12 weeks after inclusion

  2. Optimal duration of lenvatinib treatment for maximum redifferentiation to occur

    Either 6 of 12 weeks after comparing (1) fraction of patients eligible for I-131 therapy, (2) expected absorbed dose \[Gy\] per lesion or critical organ and (3) toxicity incidence and severity

    Time frame: 3 months after completed inclusion of cohort 1

  3. Extent of RAI uptake after I-131 therapy

    Assessing expected absorbed dose \[Gy\] per lesion or critical organ using intra-therapeutic I-131 SPECT/CT, whole body counting and blood sampling

    Time frame: 7 or 12 weeks after inclusion

  4. Metabolic treatment response using F-18 FDG PET

    Metabolic response will be assessed using PERCIST v1.0. Tumor response is defined as complete response, partial response, stable response or progressive disease.

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

  5. Unstimulated (TSH suppressed) thyroglobulin levels

    Assessment of biochemical treatment response

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

  6. Overall survival at 36 weeks after initation of lenvatinib

    Time frame: 9 months after inclusion

  7. Best objective response at 36 weeks after initation of lenvatinib

    Time frame: 9 months after inclusion

  8. Progression free survival at 36 weeks after initation of lenvatinib

    Time frame: 9 months after inclusion

  9. Incidence and severity of toxicities according to CTCAE 5.0

    Time frame: during 0-9 months after inclusion

  10. Quality of life using standardized questionnaire ThycaQoL

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

  11. Quality of life using standardized questionnaire RAND36

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

  12. Quality of life using standardized questionnaire EQ5D5L

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

  13. Quality of life using standardized questionnaire Distress thermometer

    Time frame: 0, 6, 12, 24, 30, 36 weeks after inclusion

Other outcomes

  1. NIS expression in biopted tumor lesion(s) at baseline and 6 weeks after lenvatinib

    An explorative endpoint of this study is to evaluate alterations at the transcriptional and translational level in biopted tumour lesions before and after lenvatinib treatment and to determine whether treatment response is related to genetical profiles

    Time frame: 0 and 6 weeks after inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dotinga M, Vriens D, van Velden F, Heijmen L, Nagarajah J, Hicks R, Kapiteijn E, de Geus-Oei LF. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Q J Nucl Med Mol Imaging. 2020 Sep;64(3):250-264. doi: 10.23736/S1824-4785.20.03264-1. PubMed 32744039 ↗
  • Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets-Schneider P, Pool M, Rietbergen DDD, de Geus-Oei LF, Kapiteijn E. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics (Basel). 2022 Dec 14;12(12):3154. doi: 10.3390/diagnostics12123154. PubMed 36553163 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2025, 35 months after the start.

Of 126 non-industry interventional studies with no phase under Thyroid Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 78. This study's planned 35 months is below that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 14 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 26, 2021
StartActual
Jan 10, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04858867
Responsible party
HW Kapiteijn (Medical Oncologist, Associate Professor Research and Treatment of Rare Cancers, Leiden University Medical Center) — Principal investigator
First posted
Apr 26, 2021
Start date
Jan 10, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Oct 10, 2023

Study contacts

Maaike Dotinga, MSc
Contact
M.Dotinga@lumc.nl
+31715263695
Dennis Vriens, MD, PhD
Contact
D.Vriens@lumc.nl
+31715299703
Ellen Kapiteijn, MD, PhD
principal investigator · LUMC
Dennis Vriens, MD, PhD
principal investigator · LUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion